Complete guide for TED patients covering active vs stable phases, teprotumumab treatment, smoking cessation importance, and the surgical rehabilitation pathway.
Thyroid eye disease (TED)—also called Graves' ophthalmopathy or thyroid-associated orbitopathy—can be one of the most challenging aspects of thyroid problems. If you're dealing with bulging eyes, double vision, or eye discomfort from TED, this guide will help you understand your condition and navigate the path from active disease through rehabilitation.
Key Takeaways
- TED has two phases: active (inflammatory) and stable (burnt out)—treatment differs by phase
- Stopping smoking is the single most important thing you can do
- Teprotumumab (Tepezza) is a breakthrough treatment for active disease
- Surgery is for stable disease and follows a specific sequence
- Multiple specialists (endocrinology, ophthalmology, oculoplastics) work together on your care
- Most patients achieve good outcomes with proper management
Understanding Thyroid Eye Disease
TED occurs when your immune system attacks tissues around the eyes. The muscles and fat behind the eyes become inflamed and enlarged, causing:
- Bulging eyes (proptosis)
- Double vision (diplopia)
- Eye redness and swelling
- Tearing and grittiness
- Pressure or pain behind the eyes
- Difficulty closing the eyes completely
- In severe cases, vision loss from optic nerve compression
Who Gets TED?
TED is most commonly associated with Graves' disease (hyperthyroidism) but can also occur with:
- Hashimoto's thyroiditis (hypothyroidism)
- Normal thyroid function (rarely)
It's more common in women, but men tend to have more severe disease.
The Two Phases of TED
Understanding which phase you're in guides treatment:
Active Phase (1-3 years)
- Immune system actively attacking eye tissues
- Symptoms may worsen or fluctuate
- Inflammation present
- Medical treatment can modify the disease
- Surgery is avoided (except emergencies)
Stable Phase (Inactive)
- Inflammation has burned out
- Symptoms no longer progressing
- Changes from active phase persist
- Surgical rehabilitation can be performed
Clinical Activity Score (CAS): Your doctor uses this scoring system to determine if TED is active. It evaluates pain, redness, swelling, and recent changes. A score of 3 or more (out of 7) suggests active disease.
Assessment and Monitoring
What Your Doctor Evaluates
Proptosis Measurement
- How far the eyes protrude forward
- Measured with an exophthalmometer
- Tracked over time
Eye Movement and Alignment
- Looking for double vision
- Measuring misalignment
- Assessing muscle restriction
Eyelid Position
- Eyelid retraction (upper lid too high)
- Inability to close eyes completely
- Lid swelling
Corneal Health
- Exposure from incomplete closure
- Dryness and irritation
Optic Nerve Function
- Color vision
- Visual field
- Pupil responses
- Vision loss suggests compression
Imaging
CT or MRI of Orbits
- Shows enlarged eye muscles
- Evaluates optic nerve crowding
- Helps plan surgery if needed
Smoking: The Critical Factor
Smoking is the single most important modifiable risk factor in TED.
Smokers have:
- More severe disease
- Longer active phase
- Poorer response to treatment
- Higher risk of vision-threatening disease
- Worse surgical outcomes
If you smoke, stopping is more important than any other treatment.
Resources for Quitting
- Talk to your doctor about smoking cessation aids
- National quitline: 1-800-QUIT-NOW
- Medications (nicotine replacement, varenicline) significantly improve success
- Even reducing smoking helps, though stopping completely is best
Treatment During Active Phase
The goal in active TED is to control inflammation and prevent permanent damage.
Selenium Supplementation
Selenium (100 mcg twice daily) has been shown in European studies to:
- Improve mild active TED
- Slow progression
- Have few side effects
It's inexpensive and often recommended early in disease.
Steroids
For moderate-to-severe active TED:
IV Steroids (Methylprednisolone)
- Given weekly or in pulses
- More effective and safer than oral steroids for TED
- 12-week courses are common
Oral Steroids
- Sometimes used but less preferred
- Higher side effect profile
Teprotumumab (Tepezza)
Teprotumumab is a game-changing treatment for TED:
How it works:
- Targets IGF-1 receptor on orbital cells
- Reduces inflammation and tissue expansion
- Given as IV infusion every 3 weeks for 8 doses
Benefits:
- Reduces proptosis (eye bulging)
- Improves double vision
- Decreases inflammatory symptoms
- Can prevent need for surgery
Considerations:
- Expensive (specialty pharmacy/insurance coordination needed)
- Side effects include muscle spasms, nausea, hearing changes
- Not suitable for everyone (discuss contraindications)
- Best in active disease
Radiation Therapy
Orbital radiotherapy may help selected patients:
- Moderate disease not responding to steroids alone
- Often combined with steroids
- Takes weeks to show benefit
Managing Specific Symptoms
For Dry, Irritated Eyes
- Preservative-free artificial tears frequently
- Lubricating ointment at night
- Moisture chamber glasses
- Humidifiers
- Taping lids at night if they don't close
For Exposure
- Eye protection outdoors (sunglasses, wrap-arounds)
- Avoid wind and dry environments
- Elevate head of bed to reduce morning swelling
For Double Vision
- Fresnel prisms on glasses (temporary)
- Patching one eye
- Permanent prisms once stable
The Surgical Rehabilitation Pathway
Surgery for TED is performed after the disease has been stable for at least 6 months. Procedures follow a specific order because each step affects the next.
Step 1: Orbital Decompression
Purpose: Reduce proptosis and relieve pressure on the optic nerve
What it involves:
- Removing bone and/or fat from the eye socket
- Creates more room for enlarged tissues
- Eyes move back into a more normal position
When it's done:
- First surgical step if needed
- Emergency decompression for optic nerve compression (even in active phase)
- Elective for appearance and comfort after stable
Step 2: Strabismus Surgery
Purpose: Correct double vision from scarred, restricted muscles
What it involves:
- Adjusting the position of eye muscles
- May be performed on one or both eyes
- Often requires adjustable sutures
When it's done:
- After orbital decompression (which can change alignment)
- Once misalignment is stable
Step 3: Eyelid Surgery
Purpose: Correct lid retraction and improve appearance
What it involves:
- Lowering the upper eyelid
- Adjusting the lower eyelid
- Removing excess tissue if needed
When it's done:
- Last in the sequence
- After eye position and alignment are addressed
Why order matters: Orbital decompression changes eye position, which affects muscle alignment. Strabismus surgery changes where the eyes point, which affects how the lids look. Doing procedures in the wrong order means repeat surgeries.
Long-Term Management
Thyroid Control
- Stable thyroid levels help stabilize TED
- Work closely with your endocrinologist
- Both over- and under-treatment can worsen TED
- Radioactive iodine treatment may temporarily worsen TED (steroid cover often used)
Ongoing Eye Care
- Regular monitoring even after TED stabilizes
- Watch for late progression (uncommon)
- Manage chronic dry eye
- Protect eyes from sun and wind
Emotional Support
TED affects appearance and quality of life. It's normal to feel:
- Self-conscious about changed appearance
- Frustrated by prolonged treatment course
- Anxious about outcomes
What helps:
- Support groups (online TED communities exist)
- Counseling if needed
- Education about expected outcomes
- Open communication with your care team
Frequently Asked Questions
Will my eyes go back to normal?
Many patients achieve significant improvement with treatment. Teprotumumab can substantially reduce bulging. Surgical rehabilitation can address remaining changes. While some patients return to near-normal appearance, others have persistent changes. Setting realistic expectations with your doctor is important.
How long does TED last?
The active phase typically lasts 1-3 years before burning out. Treatment can shorten and moderate this phase. The stable phase is permanent, but surgery can address the remaining changes.
Can TED come back after it's stable?
Reactivation can occur but is uncommon. Smoking and radioactive iodine treatment increase the risk. New or worsening symptoms should be reported to your doctor promptly.
Do I need to see multiple doctors?
Usually, yes. TED care often involves:
- Endocrinologist (thyroid management)
- Neuro-ophthalmologist or ophthalmologist (eye monitoring)
- Oculoplastic surgeon (surgical rehabilitation)
These specialists coordinate to provide comprehensive care.
Is teprotumumab right for me?
Teprotumumab is most effective in active TED. It's expensive and may have side effects. Good candidates have moderate-to-severe active disease. Your doctor can help determine if it's appropriate for your situation.
What if I can't afford teprotumumab?
Manufacturer assistance programs exist. Your doctor can explore alternatives, including steroids and radiation. Clinical trials may be available. Don't delay seeking care because of cost concerns.
Can TED cause blindness?
In severe cases, enlarged muscles can compress the optic nerve, threatening vision. This is called dysthyroid optic neuropathy (DON) and is a medical emergency requiring urgent treatment (steroids and often decompression surgery). With proper monitoring, DON can usually be detected and treated early.
When can I have surgery?
Elective surgery is performed after TED has been stable for at least 6 months. This waiting period ensures the disease won't reactivate and change surgical results. Emergency decompression for optic nerve compression may be needed during active disease.
Will I always have double vision?
Many patients' double vision improves with treatment of active disease and can be further corrected with prisms or strabismus surgery. Complete elimination of double vision isn't always possible, but significant improvement is common.
References
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. If you have concerns about thyroid eye disease or any symptoms, please consult a qualified healthcare provider.
Sources:
- Bartalena L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines. Eur J Endocrinol. 2021.
- Douglas RS, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020.
- American Thyroid Association. Graves' Eye Disease.
- Graves' Disease and Thyroid Foundation. Patient Resources.
Medically Reviewed Content
This article meets our editorial standards
- Written by:
- Hashemi Eye Care Medical Team
- Medically reviewed by:
- Board-Certified Neuro-Ophthalmologist (MD, Neuro-Ophthalmology)
- Last reviewed:
- February 3, 2025
